⌘K
Loading ticker…
As of 2026-08-24, Niagen Bioscience, Inc. Common Stock (NAGE) has a 3-month relative strength percentile of 28 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 37. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 4.3%, relative volume 0.60×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
NAGE is in a stage 4 downtrend, week 3. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -2.7% / -33.5%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
NAGE appears in 1 ETF as of Jun 2026: PSC at 0.01% weight, $249K notional.
Held by 39 ETFs · $27M across latest filings · largest weight 0.41% (LOPP).
Top 1 by value, from SEC N-PORT-P filings dated Jun 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| PSC | 0.01% | $249K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NAGE Jan avg: -5.82% median: -5.82% win: 0% σ: 0.00% n: 1 2025-03-20 → 2026-07-31 | NAGE Feb avg: -15.69% median: -15.69% win: 0% σ: 0.00% n: 1 2025-03-20 → 2026-07-31 | NAGE Mar avg: -11.76% median: -11.76% win: 0% σ: 1.29% n: 2 2025-03-20 → 2026-07-31 | NAGE Apr avg: 10.51% median: 10.51% win: 100% σ: 4.61% n: 2 2025-03-20 → 2026-07-31 | NAGE May avg: 9.72% median: 9.72% win: 50% σ: 39.76% n: 2 2025-03-20 → 2026-07-31 | NAGE Jun avg: 7.91% median: 7.91% win: 50% σ: 35.73% n: 2 2025-03-20 → 2026-07-31 | NAGE Jul avg: -14.27% median: -14.27% win: 50% σ: 29.48% n: 2 2025-03-20 → 2026-07-31 | NAGE Aug avg: 5.88% median: 5.88% win: 100% σ: 0.00% n: 1 2025-03-20 → 2026-07-31 (current) | NAGE Sep avg: -5.76% median: -5.76% win: 0% σ: 0.00% n: 1 2025-03-20 → 2026-07-31 | NAGE Oct avg: -19.18% median: -19.18% win: 0% σ: 0.00% n: 1 2025-03-20 → 2026-07-31 | NAGE Nov avg: -10.21% median: -10.21% win: 0% σ: 0.00% n: 1 2025-03-20 → 2026-07-31 | NAGE Dec avg: -6.06% median: -6.06% win: 0% σ: 0.00% n: 1 2025-03-20 → 2026-07-31 |